Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
Open accessThe DOI matches its Crossref record; 384 of the 384 references it cites were found in a registry or an index.
Abstract
A panel of experts was convened by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) to update the 2010 clinical practice guideline on Clostridium difficile infection (CDI) in adults. The update, which has incorporated recommendations for children (following the adult recommendations for epidemiology, diagnosis, and treatment), includes significant changes in the management of this infection and reflects the evolving controversy over best methods for diagnosis. Clostridium difficile remains the most important cause of healthcare-associated diarrhea and has become the most commonly identified cause of healthcare-associated infection in adults in the United States. Moreover, C. difficile has established itself as an important community pathogen. Although the prevalence of the epidemic and virulent ribotype 027 strain has declined markedly along with overall CDI rates in parts of Europe, it remains one of the most commonly identified strains in the United States where it causes a sizable minority of CDIs, especially healthcare-associated CDIs. This guideline updates recommendations regarding epidemiology, diagnosis, treatment, infection prevention, and environmental management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clostridium difficile is a Gram‐positive extracellular pathogen, which remains localized to the gastrointestinal tract but can cause severe toxin‐mediated gastrointestinal pathology, with a mortality rate of up to 6%. 67 , 68”
From The battle for iron in enteric infections (2020) · cites this paper as [68]
Citations
Cites
Multistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Stool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Self-citationBurden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641
Self-citationDethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361
An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Self-citationLoo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Self-citationGoing from evidence to recommendations
Guyatt, G. H., Oxman, A. D., Kunz, R., Falck-Ytter, Y., Vist, G. E., Liberati, A., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39493.646875.ae · Cited by 1,810
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Research works printed but not linked: 3
- Health Protection Agency, 2005, Outbreak of Clostridium difficile infection in a hospital in southeast England, CDR Wkly, 15
- Tleyjeh, 2012, Association between acid-suppression therapy and Clostridium difficile infection: a systematic review and meta-analysis, Clin Microbiol Infect, 18, 113
- Polage, 2015, Overdiagnosis of Clostridium difficile infection in the molecular test era, JAMA Intern Med, 175, 1792, 10.1001/jamainternmed.2015.4114 · DOI · Paper page
Cited by
Items 701–800 of 1,000
Bednarska, A., Bursa, D., Podlasin, R. B., Paciorek, M., Skrzat‐Klapaczyńska, A., Porowski, D., Raczyńska, J., Puła, J., Krogulec, D., Makowiecki, M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-71466-0 · Cited by 18
Rahman, A. U., Inayat, F., Ali, S., Zahid, E., & Charles, R. (2020) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-020-01272-8 · Cited by 18
Beyond Fecal Microbiota Transplantation: Developing Drugs from the Microbiome
Gerardin, Y., Timberlake, S. C., Allegretti, J. R., Smith, M. B., & Kassam, Z. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa700 · Cited by 17
The outcomes of Clostridioides difficile infection in inpatient liver transplant population
Amjad, W., Qureshi, W., Malik, A., Singh, R., & Jafri, S. (2021) · Transplant Infectious Disease · doi:10.1111/tid.13750 · Cited by 17
Probiotics in the Intensive Care Unit
Schuurman, A. R., Kullberg, R. F. J., & Wiersinga, W. J. (2022) · Antibiotics · doi:10.3390/antibiotics11020217 · Cited by 22
Validation of Clinical Risk Models for Clostridioides difficile - Attributable Outcomes
Madden, G. R., Petri, W. A., Costa, D. V. D. S., Warren, C. A., Ma, J. Z., & Sifri, C. D. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00676-22 · Cited by 17
“The addition of up to 3 empirical “points” for each of hypotension, shock, and ileus/megacolon ($1 criterion previously termed “complicated” (30) or “fulminant” infection (15, 16)) did have a maximal positive predictive value (30.”
BackgroundMethodInfluentialTauroursodeoxycholic Acid Inhibits Clostridioides difficile Toxin-Induced Apoptosis
Pike, C. M., Tam, J., Melnyk, R. A., & Theriot, C. M. (2022) · Infection and Immunity · doi:10.1128/iai.00153-22 · Cited by 18
Costa, D. V. D. S., Pham, N., Hays, R. A., Bolick, D. T., Goldbeck, S. M., Poulter, M. D., Hoang, S. C., Shin, J. H., Wu, M., & Warren, C. A. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00489-22 · Cited by 17
Villafuerte-Gálvez, J., Pollock, N. R., Alonso, C. D., Chen, X., Xu, H. J., Wang, L., White, N., Banz, A., Miller, M., Daugherty, K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac624 · Cited by 17
Self-citationClostridioides difficile spore: coat assembly and formation
Zeng, J., Wang, H., Dong, M., & Tian, G. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2119168 · Cited by 20
Liao, J. X., Appaneal, H. J., Vicent, M. L., Vyas, A., & LaPlante, K. L. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2734 · Cited by 22
Wang, W., Cao, J. X., Yang, J. H., Niu, X.-R., Liu, X., Zhai, Y., Qiang, C., Niu, Y., Li, Z., Dong, N., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02618-22 · Cited by 21
Johansen, R. L., Schouw, C. H., Madsen, T. V., Nielsen, X. C., & Engberg, J. (2023) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-023-04642-5 · Cited by 19
Genomic surveillance of Clostridioides difficile transmission and virulence in a healthcare setting
Newcomer, E. P., Fishbein, S. R. S., Zhang, K., Hink, T., Reske, K. A., Cass, C., Iqbal, Z. H., Struttmann, E. L., Burnham, C. D., Dubberke, E. R., et al. (2024) · mBio · doi:10.1128/mbio.03300-23 · Cited by 18
Self-citationHeidebrecht, H.-J., Weiss, W. J., Pulse, M., Lange, A., Gisch, K., Kliem, H., Mann, S., Pfaffl, M. W., Kulozik, U., & von Eichel‐Streiber, C. (2019) · Toxins · doi:10.3390/toxins11020098 · Cited by 18
“The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007.”
BackgroundInfluentialClostridioides difficile Infection in Chronic Kidney Disease/End-Stage Renal Disease
Ramesh, M. S., & Yee, J. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.01.001 · Cited by 18
Imwattana, K., Wangroongsarb, P., & Riley, T. V. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.03.008 · Cited by 17
Cross-sectional study of the prevalence, causes and management of hospital-onset diarrhoea
Mawer, D. P. C., Byrne, F. J., Drake, S., Brown, C., Prescott, A., Warne, B., Bousfield, R., Skittrall, J. P., Ramsay, I. D., Somasunderam, D., et al. (2019) · Journal of Hospital Infection · doi:10.1016/j.jhin.2019.05.001 · Cited by 17
Self-citationImpact of Multiplex Testing on the Identification of Pediatric Clostridiodes Difficile
Cotter, J. M., Thomas, J. F., Birkholz, M. C., Brittan, M. S., Ambroggio, L., Dolan, S. A., Pearce, K., Todd, J. K., & Dominguez, S. R. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2019.11.036 · Cited by 17
Al‐Tawfiq, J. A., Rabaan, A. A., Bazzi, A. M., Raza, S., & Noureen, M. (2020) · American Journal of Infection Control · doi:10.1016/j.ajic.2020.01.011 · Cited by 19
Takamatsu, A., Yao, K., Murakami, S., Tagashira, Y., Hasegawa, S., & Honda, H. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa298 · Cited by 18
“Published by Oxford University Press on behalf of Infectious Diseases Society of America.”
MethodYadav, D., & Khanna, S. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211009694 · Cited by 18
Chiu, C.-W., Tsai, P.-J., Lee, C., Ko, W., & Hung, Y. (2021) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2021.06.002 · Cited by 20
Atteberry, P., Biederman, B., Jesudian, A. B., Lucero, C., Brown, R. S., Verna, E. C., Sundaram, V., Fortune, B. E., & Rosenblatt, R. E. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15633 · Cited by 22
Arutyunov, A. G., Seferovic, P. M., Бакулин, И. Г., Бакулина, Н. В., Batyushin, М. М., Болдина, М. В., Krstačić, G., Μacut, D., Салухов, В. В., Shimosawa, T., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4694 · Cited by 17
Yadlapati, S., Jarrett, S. A., Lo, K. B., Sweet, J., & Judge, T. A. (2021) · Cureus · doi:10.7759/cureus.20397 · Cited by 17
“These findings may emphasize the unintended benefit of reducing nosocomial transmission via aggressive hand washing and donning and doffing protocols [7,8].”
BackgroundNagamine, T., Matsumoto, Y., & Nakamura, M. (2018) · Bioscience of Microbiota Food and Health · doi:10.12938/bmfh.18-009 · Cited by 17
Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection
Tieu, J. D., Williams, R. J., Skrepnek, G. H., & Gentry, C. A. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12771 · Cited by 17
Triggers of histologically suspected drug-induced colitis
Brechmann, T., Günther, K., Neid, M., Schmiegel, W., & Tannapfel, A. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i8.967 · Cited by 17
Shin, J. H., Chaplin, A., Hays, R. A., Kolling, G. L., Vance, S. R., Guerrant, R. L., Archbald‐Pannone, L. R., & Warren, C. A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071036 · Cited by 17
“Current guidelines from the Infectious Diseases Society of America now recommend FMT for second and subsequent recurrences of CDI (after appropriate antibiotic treatments for two or more recurrences) and subsequent rCDI [11].”
MethodRashid, T., Haghighi, F., Hasan, I., Bassères, E., Alam, M., Sharma, S. V., Lai, D., DuPont, H., & Garey, K. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01031-19 · Cited by 15
Self-citationKrůtová, M., Čapek, V., Nyčová, E., Vojackova, S., Balejová, M., Geigerová, L., Tejkalová, R., Havlinova, L., Vágnerová, I., Čermák, P., et al. (2020) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-020-00765-y · Cited by 17
Keating, J. A., Xu, T., Graham, M. B., Ramesh, M. S., Khanna, S., Dixon, J., Kates, A., Haight, K., Zhao, J., Saddler, C. M., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.17834 · Cited by 21
Aziz, M., Desai, M., Rawish, F., Viveksandeep, T. C., Albert, E., Jackson, M., & Prateek, S. (2019) · Current Clinical Pharmacology · doi:10.2174/1574884714666190328162637 · Cited by 16
Anti-virulence strategies for Clostridioides difficile infection: advances and roadblocks
Stewart, D., Anwar, F., & Vedantam, G. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1802865 · Cited by 24
Rotondo‐Trivette, S., Wang, B., Gayer, C. P., Parsana, R., Luan, Y., Sun, F., & Michail, S. K. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16496 · Cited by 17
Liu, J., Gu, L., Zhang, M., Zhang, S., Wang, M., Yu, L., & Zhang, X. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.732474 · Cited by 17
Phan, J. R., Do, D. M., Truong, M. C., Ngo, C., Phan, J. H., Sharma, S. K., Schilke, A., Mefferd, C. C., Villarama, J. V., Lai, D., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01435-21 · Cited by 17
Warren, B. G., Turner, N., Addison, R. M., Nelson, A. A., Barrett, A., Addison, B. S., Graves, A. M., Smith, B. A., Lewis, S. S., Weber, D. J., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac069 · Cited by 16
Orenstein, R. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00714-9 · Cited by 18
“Current guidelines from the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) suggest FMT as a treatment option for the second or subsequent recurrence of CDI [35].”
BackgroundRole of oral and gut microbiota in childhood obesity
Wang, W., Yan, Y., Yu, F., Zhang, W., & Su, S. (2023) · Folia Microbiologica · doi:10.1007/s12223-023-01033-3 · Cited by 20
“2020) and has been included in the guidelines for the treatment of Clostridium difficile infection (Surawicz et al. 2013; McDonald et al. 2018).”
Boicean, A., Bratu, D. G., Fleacă, R. S., Vasile, G., Shelly, L., Bîrsan, S., Bacila, C. I., & Hasegan, A. G. (2023) · Pathogens · doi:10.3390/pathogens12091149 · Cited by 18
Clostridioides (Clostridium) difficile: A silent nosocomial pathogen
Alzahrani, I. (2023) · Saudi Medical Journal · doi:10.15537/smj.2023.44.9.20230216 · Cited by 18
Review of the Impact of Biofilm Formation on Recurrent Clostridioides difficile Infection
Rubio-Mendoza, D., Martínez-Meléndez, A., Maldonado-Garza, H. J., Córdova‐Fletes, C., & Garza‐González, E. (2023) · Microorganisms · doi:10.3390/microorganisms11102525 · Cited by 16
Marcelin, J. R., Brewer, C., Beachy, M. W., Lyden, E. R., Winterboer, T., Murphy, C. N., Fey, P. D., Hood, L., & Schooneveld, T. C. V. (2019) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2019.78 · Cited by 17
Consensus on the prevention, diagnosis, and treatment of Clostridium difficile infection
y Abreu, A. T. A., Velasco, J. A. V.-R., Zavala-Solares, M. R., Remes-Troche, J. M., Carmona-Sánchez, R., Aldana-Ledesma, J. M., Camacho-Ortíz, A., Contreras-Omaña, R., Díaz-Seoane, R., Elizondo-Vázquez, C. T., et al. (2019) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2018.12.002 · Cited by 18
Evolving Strategies to Manage Clostridium difficile Colitis
Bowman, J. A., & Utter, G. H. (2019) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-019-04478-5 · Cited by 16
Kimura, T., Stanhope, S. R., & Sugitani, T. (2020) · Epidemiology and Infection · doi:10.1017/s0950268820000606 · Cited by 16
Preventing healthcare-associated infection in Switzerland: Results of a national survey
Sax, H., Schreiber, P. W., Clack, L., Ratz, D., Saint, S. K., Greene, M. T., & Kuster, S. P. (2020) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2019.351 · Cited by 16
van Rossen, T. M., van Dijk, L. J., Heymans, M. W., Dekkers, O. M., Vandenbroucke‐Grauls, C. M. J. E., & van Beurden, Y. H. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820977385 · Cited by 20
Escudero-Sánchez, R., Alijo, Á. V., Tovar, S. C., Merino, E., Fernández, S. G., Gutiérrez‐Rojas, Á., Ramos, A., Salavert, M., Hernández, I. C., Giner, L., et al. (2021) · Infection · doi:10.1007/s15010-020-01567-5 · Cited by 16
Fecal Microbiota Transplantation for Recurrent C difficile Infection During the COVID-19 Pandemic
Khanna, S., Tande, A. J., Rubin, D. T., Khoruts, A., Kahn, S. A., & Pardi, D. S. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.04.005 · Cited by 17
“Despite its investigational nature, FMT has widespread use under enforcement discretion from the United States Food and Drug Administration (FDA) owing to its remarkable success with recurrence rates dropping from an average of 60% to less than 15% seen in clinical practice and clinical trials.(1,2) It is well known t…”
BackgroundManea, E., Jipa, R. E., Milea, A., Roman, A., Neagu, G., & Hristea, A. (2021) · Romanian Journal of Internal Medicine · doi:10.2478/rjim-2021-0020 · Cited by 20
Building up a clinical microbiota profiling: a quality framework proposal
Scherz, V., Greub, G., & Bertelli, C. (2021) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2021.1975642 · Cited by 19
“(McDonald et al. 2018).”
Could Candida Overgrowth Be Involved in the Pathophysiology of Autism?
Herman, A., & Herman, A. P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11020442 · Cited by 25
Case–Control Study of Clostridium innocuum Infection, Taiwan
Chen, Y.-C., Kuo, Y., Chen, M.-C., Zhang, Y.-D., Chen, C., Le, P., & Chiu, C. (2022) · Emerging infectious diseases · doi:10.3201/eid2803.204421 · Cited by 22
Omadacycline and Clostridioides difficile : A Systematic Review of Preclinical and Clinical Evidence
Garey, K. W., Rose, W. E., Gunter, K., Serio, A. W., & Wilcox, M. H. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221089007 · Cited by 16
Self-citationRaeisi, H., Azimirad, M., Aghdaei, H. A., Yadegar, A., & Zali, M. R. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1043214 · Cited by 17
Rapid Fire: Infectious Disease Emergencies in Patients with Cancer
Charshafian, S., & Liang, S. Y. (2018) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2018.04.001 · Cited by 20
Clostridium difficile Infection and Colorectal Surgery: Is There Any Risk?
Calu, V., Toma, E.-A., Enciu, O., & Miron, A. (2019) · Medicina · doi:10.3390/medicina55100683 · Cited by 16
“Although it was initially considered a non-threatening bacterium, as it was discovered in the microbial flora of healthy newborns, Clostridium difficile has proven itself to be a very dangerous pathogen especially in the era of increased use of broad-spectrum antibiotics, most often clindamycin, penicillins, and cepha…”
BackgroundAn approach to acute severe ulcerative colitis
Sedaño, R., Quera, R., Simian, D., & Yarur, A. J. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1681974 · Cited by 17
Luo, Y., Tixier, E. N., & Grinspan, A. M. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06147-z · Cited by 21
Gupta, A. K., Wash, C., Wu, Y., Sorrentino, D. R., & Nguyen, V. Q. C. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06205-6 · Cited by 19
“The methods of CDI testing are institution-specific, though experts recommend using a multi-step algorithm incorporating toxin EIA and PCR with or without GDH to achieve the highest sensitivity and specificity [6, 7].”
MethodAljafel, N. A., Al-Shaikhy, H. H., Alnahdi, M. A., & Thabit, A. K. (2020) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2020.03.007 · Cited by 16
Maziade, P.-J., Ship, N., Sniffen, J. C., & Goldstein, E. J. C. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab414 · Cited by 15
Karimianghadim, R., Satokari, R. M., Yeo, S., Arkkila, P. E. T., Kao, D. H., & Pakpour, S. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1589704 · Cited by 18
Lim, E. C. N., & Lim, C. E. D. (2025) · Acta Microbiologica Hellenica · doi:10.3390/amh70030036 · Cited by 21
“Current IDSA/SHEA treatment guidelines recommend FMT for multiply recurrent CDI after failure of appropriate antibiotic regimens, with fidaxomicin and vancomycin as standard antimicrobial options [23].”
Critical Care Management of the Patient with Clostridioides difficile
Adelman, M. W., Woodworth, M. H., Shaffer, V. O., Martin, G. S., & Kraft, C. S. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004739 · Cited by 19
“This review will focus on treatment of fulminant disease, defined in the 2017 IDSA/SHEA guidelines as CDI with hypotension or shock, ileus, or megacolon (47).”
BackgroundMethodInfluentialClostridioides difficile Infection in Chronic Kidney Disease—An Overview for Clinicians
Dudzicz, S., Więcek, A., & Adamczak, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10020196 · Cited by 19
Berland, M., Cadiou, J., Levenez, F., Galleron, N., Quinquis, B., Thirion, F., Gauthier, F., Chatelier, E. L., Oñate, F. P., Schwintner, C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-83638-7 · Cited by 14
Turner, N., Warren, B. G., Gergen-Teague, M. F., Addison, R. M., Addison, B. S., Rutala, W. A., Weber, D. J., Sexton, D. J., & Anderson, D. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab473 · Cited by 15
Paulina Núñez, F., Quera, R., Constanza Bay, M., & Thomson, P. (2021) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2021.05.009 · Cited by 15
Panchavati, S., Zelin, N. S., Garikipati, A., Pellegrini, E., Iqbal, Z., Barnes, G., Hoffman, J. L., Calvert, J. S., Mao, Q., & Das, R. (2022) · American Journal of Infection Control · doi:10.1016/j.ajic.2021.11.012 · Cited by 22
Phillips, E. C., Warren, C. A., Ma, J. Z., & Madden, G. R. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00001-22 · Cited by 15
“1) and stratified into two treatment periods (2011–2016 and 2017–2021) marked by implementation of computerized decision support tool in December 2016 (14) and updated 2017 CDI management guidelines (15).”
BackgroundMethodMorgan, D. J., Dubberke, E. R., Hink, T., Paszkiewicz, G., Burnham, C. D., Pineles, L. L., Magder, L. S., Johnson, J. K., Leekha, S., & Harris, A. D. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac519 · Cited by 15
Self-citationOmadacycline in treating community-based infections: a review and expert perspective
Sakoulas, G., Nowak, M., & Geriak, M. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2174100 · Cited by 15
Real-world evaluation of a two-step testing algorithm for Clostridioides difficile infection
Hecker, M. T., Son, A. H., Zuccaro, P., Conti, J., & Donskey, C. J. (2023) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2022.313 · Cited by 15
Redefining Clostridioides difficile infection antibiotic response and clinical outcomes
Gonzales-Luna, A. J., Skinner, A. M., Alonso, C. D., Bouza, E., Cornely, O. A., de Meij, T. G. J., Drew, R. J., Garey, K. W., Gerding, D. N., Johnson, S., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00047-6 · Cited by 16
Self-citationThe role of gut fungi in Clostridioides difficile infection
Wang, L., Cao, Y., Lou, E., Zhao, X., & Chen, X. (2023) · Biomedical Journal · doi:10.1016/j.bj.2023.100686 · Cited by 18
“…laboratory testing for CDI, the 2017 clinical practice guidelines from the Infectious Diseases Society of America-Society for Healthcare Epidemiology of America (IDSA-SHEA) recommend excluding patients from stool testing for C. difficile if they have taken laxatives within the previous 48 h [23].”
MethodClarke, L. M., & Allegretti, J. R. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17975 · Cited by 15
“1,2,39 The tapered and pulsed vancomycin has slight variation in administration based on different society guidelines, though may be given as follows: oral vancomycin 125 mg four times daily for 10–14 days, followed by 125 mg two times daily for 7 days, followed by daily for 7 days, then every…”
BackgroundZhao, Z., Wu, Y., Geng, X., Yuan, C., Fu, Y., & Yang, G. (2024) · Medicine · doi:10.1097/md.0000000000039213 · Cited by 19
“According to the guidelines issued by the Infectious Diseases Society of America in 2018, [8] vancomycin and fidaxomicin can be the first choice for the treatment of patients with CDI for the first episode, and fidaxomicin is placed at the same recommendation level as vancomycin.”
MethodMcDonald, L. C., & Diekema, D. J. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.00782-18 · Cited by 16
Self-citationOchoa‐Hein, E., Sifuentes‐Osornio, J., Ponce‐de‐León, A., Torres‐González, P., Granados-García, V., & Galindo‐Fraga, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198212 · Cited by 15
Modified glove use for contact precautions: Health care workers’ perceptions and acceptance
Jain, S., Clezy, K. R., & McLaws, M. (2019) · American Journal of Infection Control · doi:10.1016/j.ajic.2019.01.009 · Cited by 15
Hitchcock, M. M., Holubar, M. K., Hogan, C. A., Tompkins, L. S., & Banaei, N. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.01288-19 · Cited by 15
Lee, M. S. L., Ramakrishna, B., Moss, A. C., Gold, H. S., & Branch‐Elliman, W. (2019) · Transplant Infectious Disease · doi:10.1111/tid.13216 · Cited by 15
Mayer, E. F., Marón, G. M., Dallas, R. H., Ferrolino, J. A. A., Tang, L., Sun, Y., Danziger‐Isakov, L. A., Paulsen, G. C., Fisher, B. T., Vora, S. B., et al. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15826 · Cited by 15
Ultrasensitive Clostridioides difficile Toxin Testing for Higher Diagnostic Accuracy
Sandlund, J., Davies, K., & Wilcox, M. H. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01913-19 · Cited by 15
“patients receiving laxatives and with less than three unformed stools in 24 h (22).”
BackgroundSelf-citationPrevention of Clostridium difficile Infection and Associated Diarrhea: An Unsolved Problem
Principi, N., Gnocchi, M., Gagliardi, M., Argentiero, A., Neglia, C., & Esposito, S. (2020) · Microorganisms · doi:10.3390/microorganisms8111640 · Cited by 20
Clostridium difficile and Antibiotic-associated Diarrhea
Bhattacharyya, M., Debnath, A. K., & Todi, S. K. (2020) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-23619 · Cited by 15
Han, K. N., Oh, J. H., Lee, J., Cho, Y. G., Park, J. S., Choi, J. S., Kim, D. S., & Kwon, J. S. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112894 · Cited by 15
Girão, E. S., Tavares, B. D. M., dos Santos, S. A., Gamarra, G. L., Rizek, C., Martins, R. C. R., Neto, L. V. P., Diogo, C. L., Orsi, T. D. A., Morales, H. M. P., et al. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-021-04189-3 · Cited by 17
Šamadan, L., Jeličić, M., Vince, A., & Papić, N. (2021) · Antibiotics · doi:10.3390/antibiotics10070780 · Cited by 15
Yun, J. H., Park, G. E., & Ki, H. K. (2021) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-021-00986-9 · Cited by 15
Hengel, R. L., Schroeder, C. P., Jo, J., Ritter, T. E., Nathan, R. V., Gonzales-Luna, A. J., Obi, E. N., Dillon, R. J., Anglen, L. J. V., & Garey, K. W. (2022) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-022-00456-9 · Cited by 15
“The 2017 Clinical Practice Guidelines for CDI published by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) have recognized patient-reported outcomes as an important endpoint in clinical research [8].”
BackgroundSelf-citationHyte, M., Arphai, L. J., Vaughn, C. J., & Durham, S. H. (2022) · Antibiotics · doi:10.3390/antibiotics11091211 · Cited by 15
Management of Primary and Recurrent Clostridium difficile Infection: An Update
Chai, J., & Lee, C. (2018) · Antibiotics · doi:10.3390/antibiotics7030054 · Cited by 17
“(The definitions of severe and complicated/fulminant CDI vary between guidelines, and the above definitions are based on IDSA guidelines [5,12,13]).”
BackgroundMethodInfluentialOptimizing testing for Clostridium difficile infection: A quality improvement project
Sperling, K., Priddy, A., Suntharam, N., & Feuerhake, T. (2018) · American Journal of Infection Control · doi:10.1016/j.ajic.2018.08.027 · Cited by 15
Disorders of the Colon and Rectum
Schuster, I. P., & Rajapakse, R. O. (2019) · Clinical gastroenterology · doi:10.1007/978-3-030-13377-1_8 · Cited by 13
Leal, J. R., Conly, J. M., Weaver, R. G., Wick, J., Henderson, E. A., Manns, B., & Ronksley, P. E. (2019) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2019.178 · Cited by 19
Metadata
- Authors
- McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., Loo, V., Shaklee Sammons, J., Sandora, T. J., & Wilcox, M. H.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Edward Hines, Jr. VA Hospital (US)
- Loyola University Medical Center (US)
- St. Luke's Hospital (US)
- Johns Hopkins University (US)
- Children's Hospital of Philadelphia (US)
- Washington University in St. Louis (US)
- University of Houston (US)
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
- McGill University Health Centre (CA)
- Children’s Hospital of Philadelphia, Pennsylvania
- Boston Children's Hospital (US)
- Leeds Teaching Hospitals NHS Trust (GB)
- Corresponding author
- McDonald, L Clifford
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-02-15
- Volume
- 66
- Issue
- 7
- Pages
- e1-e48
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC6018983
- OpenAlex
- W2791326569
- Cited by
- 2,690
- References
- 383
- Citations by year
- 2026: 148 · 2025: 179 · 2024: 215 · 2023: 305 · 2022: 331 · 2021: 423 · 2020: 486 · 2019: 408 · 2018: 185
- FWCI
- 228.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- Funders
- Agency for Health Research and Quality
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Keywords
- Clostridium difficile infection, nosocomial infections, healthcare-associated diarrhea, pediatric infection, diagnosis, treatment, infection control, environmental management, ribotype 027, community-acquired infections, epidemiology
- MeSH terms
- Adult, Child, Clostridium Infections, Diarrhea, Humans, Retrospective Studies, Societies, Societies, Medical, Clostridioides difficile, Infectious Disease Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.